| Acquired by | Amgen |
| Price | $380M |
| Date | 10/08 |
| Terms | Cash |
| Website | avidia.com |
| Category | Advertising |
| Phone | 650-404-2000 |
| Employees | |
| Founded | 2003 |
| Description | biopharmaceutical company |
| Total | $72.3M |
| Series B, 5/05 MedImmune Ventures Amgen Ventures | $28.5M |
| Series C, 5/06 Skyline Ventures HealthCare Ventures Alloy Ventures Amgen Ventures MedImmune Ventures Morgenthaler Ventures Texas Pacific Group | $43.8M |
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.
